Joseph E Willis
Overview
Explore the profile of Joseph E Willis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monabbati S, Fu P, Asa S, Pathak T, Willis J, Shi Q, et al.
Lab Invest
. 2024 Nov;
104(12):102168.
PMID: 39505213
Papillary thyroid carcinoma (PTC) is the most prevalent form of thyroid cancer, with a disease recurrence rate of around 20%. Lymphoid formations, which occur in nonlymphoid tissues during chronic inflammatory,...
2.
Moinova H, Verma S, Dumot J, Faulx A, Iyer P, Canto M, et al.
Am J Gastroenterol
. 2024 Apr;
119(11):2206-2214.
PMID: 38686933
Introduction: Preliminary data suggest that an encapsulated balloon (EsoCheck), coupled with a 2 methylated DNA biomarker panel (EsoGuard), detects Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) with high accuracy. The...
3.
Li Y, Wu S, Zhao Y, Dinh T, Jiang D, Selfridge J, et al.
J Clin Invest
. 2024 Jan;
134(5).
PMID: 38194275
Neutrophil extracellular traps (NETs), a web-like structure of cytosolic and granule proteins assembled on decondensed chromatin, kill pathogens and cause tissue damage in diseases. Whether NETs can kill cancer cells...
4.
Vaziri-Gohar A, Hue J, Abbas A, Graor H, Hajihassani O, Zarei M, et al.
Nat Commun
. 2023 Jun;
14(1):3823.
PMID: 37380658
Pancreatic Ductal Adenocarcinoma (PDAC) is highly resistant to chemotherapy. Effective alternative therapies have yet to emerge, as chemotherapy remains the best available systemic treatment. However, the discovery of safe and...
5.
Moinova H, Verma S, Dumot J, Faulx A, Iyer P, Canto M, et al.
medRxiv
. 2023 Jun;
PMID: 37333176
Background: We previously reported an encapsulated balloon (EsoCheck , EC), which selectively samples the distal esophagus, that coupled with a two methylated DNA biomarker panel (EsoGuard , EG), detected Barrett's...
6.
Devall M, Sun X, Eaton S, Cooper G, Willis J, Weisenberger D, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612042
Approximately 90% of colorectal cancer (CRC) develop over the age of 50, highlighting the important role of aging in CRC risk. African Americans (AAs) shoulder a greater CRC burden than...
7.
Eyerer F, Bradshaw G, Vasalos P, Laser J, Chang C, Kim A, et al.
Arch Pathol Lab Med
. 2022 Dec;
147(8):872-884.
PMID: 36508682
Context.—: Neurotrophic receptor tyrosine kinase (NTRK) fusion testing has both diagnostic and therapeutic implications for patient care. With 2 tumor-agnostic US Food and Drug Administration-approved tropomyosin receptor kinase (TRK) inhibitors,...
8.
Venkitachalam S, Babu D, Ravillah D, Katabathula R, Joseph P, Singh S, et al.
Gastroenterology
. 2022 Jul;
163(5):1228-1241.
PMID: 35870513
Background & Aims: Mechanisms contributing to the onset and progression of Barrett's (BE)-associated esophageal adenocarcinoma (EAC) remain elusive. Here, we interrogated the major signaling pathways deregulated early in the development...
9.
Yu M, Moinova H, Willbanks A, Cannon V, Wang T, Carter K, et al.
Clin Cancer Res
. 2022 Jun;
28(17):3761-3769.
PMID: 35705525
Purpose: Current endoscopy-based screening and surveillance programs have not been proven effective at decreasing esophageal adenocarcinoma (EAC) mortality, creating an unmet need for effective molecular tests for early detection of...
10.
Willis J, Eyerer F, Walk E, Vasalos P, Bradshaw G, Yohe S, et al.
Arch Pathol Lab Med
. 2022 Apr;
147(1):62-70.
PMID: 35472701
Context.—: Programmed death ligand-1 (PD-L1) immunohistochemistry companion diagnostic assays play a crucial role as predictive markers in patients being considered for immune checkpoint inhibitor therapy. However, because of a convergence...